20240101-德邦证券-医药行业周报_RDC开启核药精准诊疗时代_关注国内核药产业__17页_2mb

Market Performance and Overview

In this pharmaceutical industry weekly report, the pharmaceutical sector outperformed some sub-indectors but underperformed others. For the week ending December 29, 2023, the China Pharmaceutical Biotechnology Index increased by 23%, lagging the CSI 300 Index by 5%. Cumulative performance from the start of 2023 showed a decline of 7.1% for the pharmaceutical sector, beating the CSI 300 by 4.3%, ranking it 16th among all industries. Top performers included companies like Sahara Pharmaceutical and I-Eryi Technology. Sectors like raw materials and traditional Chinese medicine gained traction.

RDC (Radionuclide Drug Conjugates) represents a breakthrough in nuclear medicine, offering precise targeting for both diagnosis and treatment. Licensed or development drugs like Lutathera and Pluvicto are driving innovation, with global giants like Eli Lilly and Bayer accelerating investments. This could significantly boost the domestic nuclear drug industry, with companies like Dongcheng Pharmaceutical being key players.

Short-term investment focus includes core assets like Huah Medicines, Everbright Pharmaceutical, and others in innovation and pharma sectors. Long-term strategies emphasize themes such as innovation, internationalization, and traditional Chinese medicine, with stock picks including Taiji Pharmaceutical, Kizhi Biological & Pharmaceutical, and Zhongxing Pharmaceutical. Areas like gene-cell therapy and tech-driven medical devices are highlighted as growth opportunities.

Key risks involve demand uncertainties, poor company performance, and intensified competition. Overall, the sector shows signs of stabilization after a drawdown, perhaps ending, and valuations suggest potential upside for selected companies. The annual investment outlook favors innovation, international expansion, and traditional medicine for sustained growth.

Recommendations and Insights

• Short-term: Watch bottom-core assets and innovative pharma stocks.
• Long-term: Focus on high-growth sectors like nuclear drugs and traditional Chinese medicine.
• Trading insights: Entry points involve undervalued stocks and cyclicals in the new year.